All Articles

Results of the phase 2 EFFORT study support the efficacy of adavosertib, with and without olaparib, in patients with poly (ADP-ribose) polymerase inhibitor–resistant ovarian cancer, with manageable adverse events.

Final Overall Survival Results from the LIGHT Study of Olaparib Treatment in Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status

Ovarian Cancer

2021 Year in Review - Ovarian Cancer

The final overall survival analysis of the phase 2 LIGHT study indicates that olaparib therapy in patients with platinum-sensitive relapsed ovarian cancer provides overall survival benefit across patient cohorts, regardless of BRCA mutation and homologous recombination deficiency status, with a safety profile consistent with that previously described.

Phase 3b OPINION Primary Analysis of Olaparib Maintenance Monotherapy for Nongermline BRCA1/2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer

Ovarian Cancer

2021 Year in Review - Ovarian Cancer

Results of the primary analysis of the phase 3b OPINION study supported the use of olaparib maintenance therapy in patients with nongermline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer.

Professional Oncology Navigation Task Force Releases Oncology Navigation Standards of Professional Practice

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie

March 2022 Vol 13, No 3

Patient Experience as a Measurement of Successful Navigation: Why the Patient Experience Matters, and How You Can Effectively Measure It

AONN+ Standardized Metrics

March 2022 Vol 13, No 3

AONN+ Metrics specific to patient experience can help you to measure the success of your navigation program.

Multiple Myeloma: Overview, Treatments, and the Navigator’s Role in Clinical Trials

By Chelsea Passwater, DNP, APRN, AGCNS-BC, OCN; Denise Brigham, RN, MPH, OCN, CCRC; Shana Smith, MSN, RN, OCN

Multiple Myeloma, Clinical Trials

March 2022 Vol 13, No 3